Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HETRAZAN vs EMVERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Treatment of lymphatic filariasis (Wuchereria bancrofti, Brugia malayi),Treatment of tropical pulmonary eosinophilia,Treatment of loiasis (Loa loa)
Treatment of trichuriasis (whipworm infection),Treatment of enterobiasis (pinworm infection),Treatment of ascariasis (roundworm infection),Treatment of hookworm infections (Ancylostoma duodenale and Necator americanus),Off-label: Treatment of capillariasis, toxocariasis, and other helminth infections
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; may be prolonged in renal impairment.
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Diethylcarbamazine is rapidly absorbed and extensively metabolized in the liver via N-oxidation and N-demethylation, involving multiple CYP enzymes. The major metabolite is diethylcarbamazine N-oxide.
Primarily hepatic; metabolized by microsomal enzymes (CYP450) to major metabolite 2-aminomebendazole, which is less active; also undergoes further metabolism.
Renal excretion of unchanged drug accounts for approximately 50-60% of elimination; the remainder is metabolized hepatically with metabolites excreted in urine. Fecal elimination is minimal (<5%).
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Protein binding is approximately 10-20%, primarily to albumin.
~90-95% bound to plasma proteins, primarily albumin.
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution.
~1-2 L/kg; indicates extensive tissue distribution.
Oral bioavailability is approximately 90% due to well absorption from the gastrointestinal tract.
Oral: ~22-40% due to first-pass metabolism; improved with food.
No specific GFR-based dose modifications available; use with caution in renal impairment due to potential accumulation. Monitor for adverse effects.
No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Contraindicated.
No adjustment for mild (Child-Pugh A) or moderate (Child-Pugh B) impairment. Avoid use in severe hepatic impairment (Child-Pugh C) due to increased risk of toxicity.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg. For children <15 kg, dosage based on 1 mg/kg initially, then increase gradually.
Children ≥2 years: 100 mg orally twice daily for 3 days. Children <2 years: safety not established; use only if potential benefit outweighs risk.
Initiate at lower end of dosing range (2 mg/kg per dose) due to potential age-related decrease in renal function. Monitor closely for adverse effects.
No specific adjustment required; use standard adult dosing. Monitor for adverse effects due to potential age-related renal or hepatic decline.
HETRAZAN is contraindicated in patients with onchocerciasis (river blindness) due to the risk of severe Mazzotti reaction, including ocular damage and encephalopathy. Treatment should not be initiated in areas where onchocerciasis is endemic or in patients with suspected onchocerciasis.
None.
Severe allergic or inflammatory reactions (Mazzotti reaction) in patients with onchocerciasis; encephalopathy in loiasis with high microfilarial loads; ocular damage (e.g., uveitis, optic neuritis) in onchocerciasis; thrombocytopenia; aminotransferase elevations; use in pregnancy only if clearly needed.
Risk of neutropenia and agranulocytosis, especially with high doses or prolonged use,May cause bone marrow suppression; monitor blood counts in prolonged therapy,Hepatotoxicity reported; use caution in hepatic impairment,Seizures have occurred, particularly in patients with history of seizures,Not recommended in pregnancy (pregnancy category C); embryotoxic and teratogenic in animals
Onchocerciasis (active or suspected),High-grade Loa loa microfilaremia (>8000 microfilariae/m L),Hypersensitivity to diethylcarbamazine or any component of the formulation
Hypersensitivity to mebendazole or any component of the formulation,Absolute contraindication: Known hypersensitivity
Grapefruit juice may inhibit CYP450 metabolism; avoid concurrent intake. Administer with food to reduce gastrointestinal distress.
No significant food interactions; absorption is enhanced by fatty foods but not required for efficacy in enterobiasis. Avoid alcohol due to potential hepatotoxicity.
Animal studies have not been conducted; no adequate human data. Use only if benefit outweighs risk. No known teratogenic effects in first trimester; limited data in second and third trimesters.
FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed. Risk cannot be ruled out, especially in the first trimester.
Excreted into breast milk; M/P ratio unknown. Use with caution due to potential for adverse effects in infant.
Excretion in human milk unknown. Caution should be exercised when administered to a nursing woman. M/P ratio not available.
No specific dose adjustments recommended; pharmacokinetics may be altered but data insufficient to guide changes.
No dose adjustment is recommended solely due to pregnancy, as pharmacokinetic changes are not well characterized. Use standard dosing: mebendazole 100 mg twice daily for 3 days for pinworm (or single 100 mg dose). For other indications, follow standard protocols.
HETRAZAN (diethylcarbamazine) is primarily used for lymphatic filariasis and loiasis; monitor for Mazzotti reaction (fever, rash, arthralgias) in high microfilarial loads; contraindicated in onchocerciasis due to severe ocular reactions; administer with food to reduce GI upset.
EMVERM (mebendazole) is poorly absorbed systemically, making it ideal for intraluminal helminth infections. Administer with fatty meal to enhance absorption when systemic effect (e.g., for trichinosis) is desired. Avoid in pregnancy (FDA Category C). Tablets may be chewed, swallowed, or crushed. Monitor for rare agranulocytosis, especially with concurrent metronidazole or high doses.
Take with food to minimize nausea.,Report any severe itching, rash, fever, or vision changes.,Complete full course even if symptoms improve.,Avoid grapefruit juice which may affect metabolism.,May cause dizziness or drowsiness; avoid driving if affected.
Take exactly as prescribed; a second course may be needed if reinfection occurs.,Tablets can be chewed, crushed, or swallowed whole with or without food.,Mebendazole works by preventing worms from absorbing sugar, causing their death.,Strict hand hygiene and laundering of bedding/clothing to prevent reinfection.,Treat all household members if pinworm outbreak; withhold treatment in pregnancy unless essential.,Notify provider if fever, sore throat, or unusual bleeding/bruising (agranulocytosis warning).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HETRAZAN vs EMVERM, answered by our medical review team.
HETRAZAN is a Anthelmintic that works by Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.. EMVERM is a Anthelmintic that works by Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HETRAZAN and EMVERM depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HETRAZAN is: 2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.. The standard adult dose of EMVERM is: Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HETRAZAN and EMVERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HETRAZAN is classified as Category C. Animal studies have not been conducted; no adequate human data. Use only if benefit outweighs risk. No known teratogenic effects in first trimester; limited data in second and thir. EMVERM is classified as Category C. FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.